Business Wire

Medicago Announces Positive Phase 1 Results for Its COVID-19 Vaccine Candidate

Share

Medicago, a biopharmaceutical company headquartered in Quebec City, is pleased to report interim results of the Phase 1 clinical trial of its plant-derived vaccine for COVID-19. The results of the trial demonstrated that 100 per cent of subjects developed a promising antibody response after two doses of Medicago’s COVID-19 adjuvanted vaccine candidate.

“These are very promising results. After two doses, the adjuvanted vaccine candidate induced robust neutralizing antibody and cellular immune responses which is encouraging and support further clinical evaluation,” said Nathalie Landry, Executive Vice President, Scientific and Medical Affairs at Medicago. “We also observed that the antibody levels were higher after vaccination than those observed in convalescent sera from people who recovered from the disease.”

There were no severe adverse events reported and reactogenicity events were generally mild to moderate and short in duration.

The Phase 1 clinical trial was a randomized, partially blinded study of 180 healthy subjects, male and female aged 18-55, and evaluated dosages of 3.75, 7.5 or 15 micrograms of the recombinant Coronavirus Virus-Like Particle (CoVLP) vaccine candidate alone or with an adjuvant in a prime-boost regimen. Medicago tested its vaccine candidate with each of the two adjuvants – GSK’s proprietary pandemic adjuvant technology and Dynavax’s CpG 1018™. An adjuvant can be of particular importance in a pandemic situation as it may boost the immune response and reduce the amount of antigen required per dose, allowing more vaccine doses to be produced and therefore allowing immunization of the greatest number of people. Significant humoral and cell-mediated immune responses have been observed with both adjuvants. Based on the Phase 1 data, Medicago plans to proceed with the Phase 2/3 clinical trial for its COVID-19 vaccine candidate, subject to regulatory approval.

“The positive results of our Phase 1 clinical trial are a step forward in the fight against the COVID-19 pandemic and we are confidently moving forward to our Phase 2/3 trial. We’re pleased that Medicago’s innovative manufacturing technology is helping to diversify the classes of COVID-19 vaccines candidates in development. In addition to supplying up to 76 million doses to the Government of Canada, we are ready to participate globally in the fight against COVID-19,” said Dr. Bruce D. Clark, President and CEO of Medicago. “We would like to express our gratitude to the clinical trial participants who have generously dedicated their time to support the advancement of Medicago’s COVID-19 vaccine candidate. We also would like to extend our thanks to our partners GSK and Dynavax, as well as the clinical investigators.”

The data from the interim analysis have been published on an online preprint server at medRxiv.org.

About Phase 1 results summary

  • Side effects were mainly mild to moderate and of short duration with no serious adverse events. Safety follow-up continues.
  • Phase 1 immunogenicity results demonstrate that adjuvants have the potential to improve humoral and cellular immune responses compared to the non-adjuvanted formulations.
  • All subjects in the group with GSK’s pandemic adjuvant developed anti-spike IgG antibodies after a single dose of vaccine – either 3.75, 7.5 and 15 µg.
  • 100 per cent of participants who received an adjuvanted formulation developed neutralizing antibody responses after Dose 2 for all dose groups.
  • Anti-spike IgG and viral neutralization responses compared favorably to responses from COVID-19 positive patients outside of the study.
  • GSK’s pandemic adjuvant was dose-sparing, with the lower 3.75 µg dose of CoVLP performing comparably with the 7.5 or the 15 µg doses.
  • Cellular Th1 immune responses of participants who received 3.75 or 7.5 µg doses were significantly higher in the adjuvanted formulations
  • CoVLP finished product is a liquid formulation that can be stored at 2°C to 8°C, easing cold chain management with existing vaccine infrastructure.

About Medicago

Medicago is a biopharmaceutical company and pioneer in plant-derived therapeutics. Founded in 1999 with the belief that innovative approaches and rigorous research would bring new solutions in healthcare.

Our mission is to improve global health outcomes by leveraging innovative plant-based technologies for rapid responses to emerging global healthcare challenges. Medicago is committed to advancing therapeutics against life-threatening diseases worldwide. Our team includes over 450 scientific experts and employees in Canada and the United States and academic affiliations in Europe and South Africa.

Medicago has previously demonstrated its capability to be a first responder in a flu pandemic. In 2009, the company produced a research-grade vaccine candidate against H1N1 in just 19 days. In 2012, Medicago manufactured 10 million doses of a monovalent influenza vaccine candidate within one month for the Defense Advanced Research Projects Agency (DARPA), part of the U.S. Department of Defense. In 2015, Medicago also demonstrated in principle that it could rapidly produce an anti-Ebola monoclonal antibody cocktail for the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services.

For more information: www.medicago.com

To learn more about our plant-based technology: Video / Website

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media contact (English):
Alissa Von Bargen
+1-647-234-5975
Alissa.VonBargen@gcicanada.com

Media contact (French):
Marie-Pier Côté
+ 1-418-999-4847
mpcote@tactconseil.ca

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Aizon Launches New AI-powered eBR Light Solution to Enhance Manufacturing Productivity in Collaboration with Euroapi18.9.2024 19:00:00 EEST | Press release

Aizon, an Artificial Intelligence (AI) SaaS provider dedicated to transforming pharmaceutical manufacturing operations, is launching a new product called Aizon Execute, an innovative eBR (Electronic Batch Record) software product, developed in collaboration with Euroapi, a leading global API manufacturer. This collaboration was born out of the need to digitize operations towards more data-driven manufacturing - focusing on the essential user needs while avoiding the heavy lift currently associated with going paperless in manufacturing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240918037613/en/ Aizon Execute is a modern, user-centric, lightweight product designed to adapt to small-scale productions and highly flexible plants like chemical API CDMOs - and has the potential to become the true backbone of digital transformation journeys. Aizon Execute light eBR is designed to facilitate the rapid transition from paper-based

Headline Closes $865 Million to Invest in Growth-Stage Tech Companies18.9.2024 18:53:00 EEST | Press release

Headline today announced Headline Global Growth IV with $865M1 of capital committed to the strategy to support companies at their Growth inflection points, Series B and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240918812241/en/ Headline's Global Growth Equity Team (Photo: Business Wire) The Global Growth strategy has three distinct advantages: a diverse and experienced team, extensive geographic coverage, and advanced in-house built technology for sourcing (Searchlight) and analytics (DeepDive). Led by seasoned Growth investor Shalini Rao, the Growth team is committed to identifying and nurturing "Paradiesvögel"—tenacious technology founders poised for global success. Recent team additions to Headline Global Growth include Nancy Xiao, Trevor Neff, Reda Bensaid, Jake Horwitz and Austin Hack, all of whom will work out of Headline’s San Francisco and European offices. Global Growth IV represents the evolution of gr

New Garmin G5000 Avionics Upgrade Now Available for Cessna Citation XLS Aircraft at Textron Aviation Service Centers18.9.2024 18:00:00 EEST | Press release

Textron Aviation today announced customers can now upgrade their Cessna Citation XLS+ and Citation XLS Gen2 aircraft with the Garmin G5000 integrated flight deck following Garmin’s receipt of FAA supplemental type certification (STC) for the avionics upgrade. Customers can have the upgrade installed at selected domestic Textron Aviation Service Centers to add significant technological advances and new capabilities to their aircraft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240918046690/en/ New Garmin G5000 avionics upgrade now available for Cessna Citation XLS aircraft at Textron Aviation Service Centers. (Photo: Garmin, Textron Aviation) Beechcraft, Cessna and Hawker customers receive factory-direct support, maintenance and modifications by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, through a global network of service and part centers, mobile service units and 24/7 1CALL AOG support. “The G5000 avionic

ProAmpac Brings Fiberization and Sustainable Packaging Innovation to FACHPACK 202418.9.2024 17:45:00 EEST | Press release

ProAmpac, a leader in flexible packaging and material science, will showcase its latest sustainable packaging solutions at FACHPACK 2024 from September 24-26 in Nuremberg, Germany. At stand 5-126, ProAmpac will present advanced offerings such as ProActive Recyclable® FibreSculpt, ProActive Intelligence® Moisture Protect MP-1000, and the ProActive Recyclable® RP-1050, alongside its RAP Packaging line of fiber-based food-to-go solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240918028305/en/ FibreSculpt (Photo: Business Wire) “We invite attendees to explore ProAmpac’s innovative solutions driving the fiberization of packaging,” said Alex Baumgartner, president of ProAmpac’s European division. “From our MP-1000 technology, which transforms moisture control in powdered beverages and nutraceuticals, to our fiber-based food-to-go packaging, these advancements meet the growing demand for sustainable, high-performance packa

Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries18.9.2024 17:00:00 EEST | Press release

Takeda (TOKYO:4502/NYSE: TAK) today committed JPY4.6 billion (Approx. USD 32 million) to five new Global Corporate Social Responsibility (CSR) partners as part of the company’s ongoing commitment to improving health systems resiliency in low and middle-income countries around the world. This commitment demonstrates Takeda’s focus on tackling systemic disparities and supporting local leadership in strengthening health infrastructure, empowering health workforce, and increasing local knowledge and capacity to improve equitable and sustainable healthcare access and delivery. By 2030, these new collaborations are anticipated to extend Takeda’s impact to 27 million people across 93 countries, raising the total contributions from Takeda’s Global CSR Program to over JPY 28.8 billion (Approx. USD 199.1 million) across 34 significant partnerships since it began in 2016. The five new partners were selected by more than 22,000 Takeda employees across 80 countries and regions through a company-wid

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye